Home Featured Page 263

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

Red Light Holland to Partner with Leading Fresh and Dried Mushroom...

PT249 – Hadas Alterman, Serena Wu, and Adriana Kertzer of Plant...

Filament Announces Shareholder Approval of Amalgamation and Closing of Private Placement...

Psychedelics and Perception Part 1: The First Era of Research

Red Light Holland Provides Initial FAQ in connection with Transaction with...

Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications;...

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Interview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

Red Light Holland to Partner with Leading Fresh and Dried Mushroom...

PT249 – Hadas Alterman, Serena Wu, and Adriana Kertzer of Plant...

Filament Announces Shareholder Approval of Amalgamation and Closing of Private Placement...

Psychedelics and Perception Part 1: The First Era of Research

Red Light Holland Provides Initial FAQ in connection with Transaction with...

Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications;...

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY